**Proteins** 

# **Product** Data Sheet

## USP7-IN-9

Cat. No.: HY-146887 CAS No.: 2444374-01-8 Molecular Formula:  $C_{32}H_{33}ClF_6N_6O_8$ 

Molecular Weight: 779.08

Target: Deubiquitinase; Apoptosis

Pathway: Cell Cycle/DNA Damage; Apoptosis

4°C, sealed storage, away from moisture Storage:

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (128.36 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.2836 mL	6.4178 mL	12.8357 mL
	5 mM	0.2567 mL	1.2836 mL	2.5671 mL
	10 mM	0.1284 mL	0.6418 mL	1.2836 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description  $USP7-IN-9\ is\ a\ highly\ potent\ ubiquitin-specific\ protease\ 7\ (USP7)\ inhibitor\ with\ an\ IC_{50}\ value\ of\ 40.8\ nM.\ USP7-IN-9\ can$ induce apoptosis and arrest cell progression at G0/G1 and S phases in RS4; 11 cells. USP7-IN-9 reduces the protein levels of oncoproteins MDM2 and DNMT1 and increases the protein levels of tumor suppressors p53 and p21<sup>[1]</sup>.

IC<sub>50</sub>: 40.8 nM (USP7)<sup>[1]</sup> IC<sub>50</sub> & Target

USP7-IN-9 (compound L55) (0-50  $\mu$ M; 3 or 6 days) exhibits inhibitory activity against cancer cells<sup>[1]</sup>. In Vitro

> USP7-IN-9 (1  $\mu$ M; 0-72 hours) reduces the proportions of G2/M cells, and does not change the proportions of G0/G1 and S cells<sup>[1]</sup>.

USP7-IN-9 (0.1-1 μM; 24 hours) reduces the protein levels of MDM2 and DNMT1 in a dose-dependent manner, and increases the protein levels of p53 and p21<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

LNCaP, RS4; 11, HCT 116, NB4, K562 and HuH-7 cells<sup>[1]</sup> Cell Line:

Concentration:	0-50 μΜ		
Incubation Time:	LNCaP, 6 days; RS4; 11, HCT 116, HuH-7, K562 and NB4, 3 days		
Result:	Exhibited high inhibitory activity against LNCaP and RS4; 11 cells, with IC <sub>50</sub> s of 29.6 nM and 41.6 nM, respectively, and weak inhibitory activity on HCT 116, NB4, K562 and HuH-cells.		
Cell Cycle Analysis			
Cell Line:	RS4; $11  cells^{[1]}$		
Concentration:	1μΜ		
Incubation Time:	0, 24, 48 and 72 hours		
Result:	Reduced the proportions of G2/M cells, while the proportions of G0/G1 and S cells were not apparently altered.		
Western Blot Analysis			
Cell Line:	RS4; 11 cells <sup>[1]</sup>		
Concentration:	0.1, 0.3 and 1 μM		
Incubation Time:	24 hours		
Result:	Reduced the protein levels of MDM2 and DNMT1 in a dose-dependent manner, and increased the protein levels of p53 and p21.		

#### **REFERENCES**

[1]. Li M, Liu S, Chen H, et al. N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure-activity relationships and X-ray crystallographic studies. Eur J Med Chem. 2020;199:112279.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA